Articles tagged "Antibodies"

2020 American Transplant Congress
Peripheral Blood RNA Sequencing Unravels a Differential Role of Coding and Non-Coding Genes by Types of Kidney Allograft Rejection
S. Sur¹, S. Pineda¹, T. Sigdel¹, M. Sirota¹, O. Bestard², M. Sarwal¹
¹University of California San Francisco, San Francisco, CA, ²Laboratory of Experimental Nephrology and Transplantation, Barcelona, Spain
*Purpose: Peripheral blood molecular patterns characterizing the different effector immune pathways driving kidney allograft rejection remain to be fully completely elucidated, to more fully type…
2020 American Transplant Congress
Carfilzomib-Based Desensitization: Effects on HLA, Non-HLA, Auto, and Antiviral Antibodies
S. Tremblay¹, E. Portwood¹, A. R. Shields², R. R. Alloway¹, P. A. Brailey¹, E. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²U Cincinnati, Christ Hospital, Cincinnati, OH
*Purpose: An important question in plasma cell (PC) therapies is the specificity of therapy for PC populations. It is known that plasmablast populations are exquisitely…
2020 American Transplant Congress
dd-cfDNA as a Risk Factor for Initiating De-Novo Donor Specific Antibodies in Heart Transplantation
E. DePasquale¹, J. Kobashigawa², S. Pinney³, K. Khush⁴
¹Keck Hospital of USC, Los Angeles, CA, ²Cedars-Sinai, Beverly Hills, CA, ³Mount Sinai Health System, New York, NY, ⁴Stanford University, Stanford, CA
*Purpose: We hypothesize that subclinical inflammation, resulting in molecular injury of the cardiac allograft, may contribute to sensitization of the recipients’ immune system. Antigenic presentation…
2020 American Transplant Congress
Late Intra-Patient Tacrolimus Variability Predicts De Novo Donor-Specific Antibody and Graft Loss
J. Lee¹, E. Kim¹, S. Yang², S. Kim¹, H. Choi³, B. Kim⁴, M. Ju⁵, M. Kim², S. Kim², Y. Kim², K. Huh²
¹Department of Transplantation Surgery, Severance Hospital, Seoul, Korea, Republic of, ²Department of Transplantation Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁴Department of Internal Medicine, Severance Hospital, Seoul, Korea, Republic of, ⁵Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
*Purpose: Intra-patient variability (IPV) of tacrolimus level has been associated with poor outcomes after kidney transplantation. However, these findings were limited mainly to measurements early…
2020 American Transplant Congress
ABO Self-Tolerance in a Mouse Model: Evidence of Tolerance at B Cell but Not T Cell Level
I. Adam, B. Motyka, K. Tao, L. West
Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada
*Purpose: We showed that human infants become tolerant to donor A/B-antigens (Ag) after ABO-incompatible heart transplantation (ABOi-HTx) by mechanisms not well-defined. To expand ABOi-HTx effectively…
2020 American Transplant Congress
In-Vivo Application of Ides (Imlifidase) in Nonhuman Primates Results in Xenoreactive Desensitization: A Novel Anti-Humoral Therapy
B. P. Lovasik¹, A. J. Matar¹, D. A. Faber¹, D. V. Mathews¹, C. Breeden¹, S. C. Kim¹, A. J. Tector², A. Robertson³, C. Kjellman³, A. B. Adams¹
¹Emory University School of Medicine, Atlanta, GA, ²University of Miami, Miami, FL, ³HANSA Biopharma, Lund, Sweden
*Purpose: Antibody-mediated rejection is a formidable barrier to xenograft survival. A novel anti-humoral IdeS therapy, which cleaves serum IgG, represents a promising therapy to reduce…
2020 American Transplant Congress
Peak DSA Levels Pre-Transplant but Not at Transplant Predict Graft Survival
A. Y. Choi¹, D. Olaso¹, T. Risoli Jr², M. Kuchibhatla², Z. Fitch³, R. Schmitz³, P. M. Schroder³, A. Jackson³, M. Manook³, J. Yoon³, A. B. Farris⁴, J. Kwun³, S. J. Knechtle³
¹Duke University School of Medicine, Durham, NC, ²Duke Biostatistics, Epidemiology, and Research Design Core, Duke University, Durham, NC, ³Department of Surgery, Duke University Medical Center, Durham, NC, ⁴Department of Pathology, Emory University Hospital, Atlanta, GA
*Purpose: Immunization to major histocompatibility complex (MHC) antigens is a barrier in kidney transplantation (KTx) due to higher risk of antibody-mediated rejection (AMR) and graft…
2020 American Transplant Congress
Dominant Negative Polymorphisms in TNFRSF13B are Associated with Poor Transplant Outcome
M. G. de Mattos-Barbosa¹, E. T. Luning Prak², E. Farkash³, J. L. Platt⁴, M. Cascalho⁴
¹Transplant Surgery, University of Michigan, Ann Arbor, MI, ²Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Pathology, University of Michigan, Ann Arbor, MI, ⁴Transplant Surgery and Microbiology and Immunology, University of Michigan, Ann Arbor, MI
*Purpose: Transmembrane Activator and CAML Interactor (TACI) is a highly polymorphic receptor that controls B cell activation and differentiation into antibody-secreting cells. Allelic variants of…
2020 American Transplant Congress
Association between Longer Hospitalization and Development of De Novo Donor Specific Antibody in Simultaneous Liver-Kidney Transplant Recipients
M. Yazawa¹, O. Cseprekal², R. A. Helmick¹, M. Talwar¹, V. Balaraman¹, P. S. Podila³, S. Fossey⁴, S. K. Satapathy⁵, J. D. Eason¹, M. Z. Molnar¹
¹James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN, ²Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary, ³Faith & Health Division, Methodist Le Bonheur Healthcare, Memphis, TN, ⁴Transplant Immunology Laboratory, DCI Inc., Nashville, TN, ⁵Sandra Atlas Bass Center for Liver Diseases & Transplantation, Northshore University Hospital/Northwell Health, Manhasset, NY
*Purpose: De novo Donor Specific Antibodies (DSA) are considered a risk factor for worsening kidney allograft outcomes in recipients after simultaneous liver-kidney transplantation (SLK). No…
2020 American Transplant Congress
Profiling Non-HLA Antibodies in Antibody-Mediated Rejection Following Cardiac Transplantation
S. B. See¹, B. S. Mantell², K. J. Clerkin³, B. Ray⁴, E. R. Vasilescu⁵, C. Marboe⁵, Y. Naka⁶, S. Restaino³, P. C. Colombo³, L. Addonizio², M. A. Farr³, E. Zorn¹
¹Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY, ²Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, ³Department of Medicine, Columbia University Irving Medical Center, New York, NY, ⁴Research and Development, Immucor, Waukesha, WI, ⁵Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, ⁶Department of Surgery, Columbia University Irving Medical Center, New York, NY
*Purpose: Antibody-mediated rejection (AMR) driven by the development of donor-specific antibodies (DSA) directed against mismatched donor HLA is a major risk factor for graft loss…